Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment

JAMA Dermatol. 2024 Feb 1;160(2):237-238. doi: 10.1001/jamadermatol.2023.4744.
No abstract available

Plain language summary

This case report describes a 14-year-old girl with juvenile dermatomyositis who presented with a 6-year history of a pruritic, photosensitive eruption involving her face, neck, trunk, and extremities and was successfully treated with anifrolumab.

MeSH terms

  • Administration, Cutaneous
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Dermatomyositis* / drug therapy
  • Humans
  • Skin

Substances

  • anifrolumab
  • Antibodies, Monoclonal, Humanized